CARE embarks on an unprecedented mission to get ready for coming COVID-19 waves and new coronavirus outbreaks.

The world needs to prepare for a future wherein waves of COVID-19 and other coronavirus outbreaks become part of the landscape. Apart from studying the potential of existing drugs to treat COVID-19 in the short-term, the CARE consortium are working on preparing for a better response to outbreaks that will inevitably occur much further down the road…

Read the full article

Launch of CARE Press release “Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats”

Read more

Leaders of the IMI CARE and SCORE consortia joined an Innovation Task Force (ITF) meeting with the European Medicines Agency (EMA) on September 21, 2020. Establishing an exchange between the consortia and the EMA at an early stage, the participants focused in this preparatory discussion on scientific and regulatory topics relevant to the development of SARS-CoV-2 antivirals complementing and reinforcing existing formal procedures.

Virtual meeting week

A fruitful week to gather the Consortium partners and discuss the Work Packages. The coordinators reiterated that the overarching vision of CARE is to develop appropriate therapeutic agents to address the immediate patient need and to prepare use in any future outbreaks for any type of coronaviruses. The aim of this ambitious project is to bring solutions through proof of concept as soon as possible.

It was a promising meeting week.

The CARE project officially started on April 1st 2020.

IMI launched the IMI-2 Call 21 on COVID on March 3, 2020, and the project was submitted on March 31, 2020. The results were known on May 11, 2020, and CARE was selected together with 7 other consortia. The CARE project started retrospectively on April 1, 2020.

CARE Partner perspectives – Cyril Dousson

22 February 2024
CARE Partner perspectives - Cyril Dousson The Covid-19 pandemic is over so what is the value of CARE? Principal investigators comment on CARE's importance for future pandemic preparedness. Today, see the response from Cyril Dousson, CEO of Ai-biopharma.